implantable tissue News
-
Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...
-
Chinese scientists implant 3D printed tissue into monkeys
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust. Trial Try full digital access and see why over 1 million readers subscribe to the FT $1 for 4 weeks Then $69 per month New customers only Cancel anytime during ...
-
Fibralign receives ISO 13485:2012 Certification
Fibralign received Certification Notification on February 18, 2018 from notifying body DEKRA Certification B. V. that it’s management system meets the requirements of EN ISO 13486:2016:2012 + AC:2012. The scope of the certification is for the design, development, manufacture and distribution of porcine collagen scaffold implants used for soft tissue repair and support, ...
-
Bioprinting: Poietis announces the award of a third new major European patent
Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology: Patent No. EP3233499 entitled «Laser printing method and device for implementing said method», which covers in particular the process of bioprinting upwards, previously delivered in France, and in Europe on March 21st, 2019. As a reminder ...
By Poietis
-
EyeYon Medical’s Q3/20 Newsletter
Vision accessibility for anyone, anywhere Ready for use, Artificial Endothelial Layer EndoArt® aims to eliminate the need for donor tissue in corneal edema treatment. All you wanted to know about the disruptive EndoArt® Artificial Endothelial Layer at one publication! Take a look at this exciting article with the latest, most updated results of our First in Human trial, already ...
-
3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial
3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial is ...
-
Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
By Poietis
-
Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts
Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...
By Poietis
-
Poietis and Prometheus, division of skeletal tissue engineering of KU Leuven, enter into a Collaborative Research Agreement focused on 3D Bioprinting for skeletal ATMPs.
Poietis, leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. Prometheus focuses on the bench-to-bedside clinical translation of increasingly ...
By Poietis
-
Xeltis receives €15M funding from EIC Accelerator
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, ...
By XELTIS BV
-
Poietis signs a clinical research collaboration contract with the Assistance Publique – Hôpitaux de Marseille (AP-HM) to prepare the first clinical trial of a bioprinted skin.
Poietis, leading bioprinting company, and the « Assistance Publique – Hôpitaux de Marseille » (AP-HM) announced today that they have entered into a partnership through the signature the 20th of January of a clinical research collaboration contract on a bioprinted tissue engineering product. The objective of this agreement is to carry out within two years a Phase I clinical ...
By Poietis
-
Nalu Micro-Implantable Pulse Generator Receives Award for Implanted Medical Device Innovation and Health Benefits
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announces its Nalu micro-Implantable Pulse Generator (mIPG) was named the Implant and Tissue-Replacement device Gold Winner at the 2021 Medical Design Excellence Awards (MDEA). The MDEA is a prestigious award that ...
-
CD Formulation Newly Launches 100+ Raw Materials for Preparation of Microspheres and Microneedles
Microsphere formulation has been highlighted as a promising dosage form in clinical practice due to its ability to significantly improve patient convenience and compliance. As a trustworthy partner in the field of pharmaceutical formulation, CD Formulation has newly introduced a range of raw materials for the production of microspheres and microneedles, which are highly expected to advance ...
-
Photodisinfection successfully eradicates pathogens associated with replacement joint infections
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. These results were presented at the recent Swiss Society for Microbiology (SSM) Annual Congress 2022 in Lausanne, Switzerland. ...
-
ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc products to U.S. Department of Defense (DoD) medical facilities. Through this agreement, the ReShape ...
-
Sterigenics International and Noxilizer announce partnership to provide NO2 sterilization for pharmaceutical, biotech and medical device products
October 3, 2017 (Baltimore, MD and Broadview Heights, OH) Noxilizer, Inc. and Sterigenics International LLC announce the signing of a global agreement that will make Sterigenics the exclusive worldwide provider of nitrogen dioxide (NO2) contract sterilization services, as well as feasibility and research studies, to the pharmaceutical, biotech and medical device manufacturing industries. ...
-
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved Xplore2/Pivotal study. ...
By XELTIS BV
-
Biorez Announces FDA 510(k) Clearance of Its Proprietary BioBrace Implant Technology
Biorez Inc., a New Haven start-up advancing tendon and ligament healing, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for two sizes of its BioBrace Implant. This new biocomposite soft tissue scaffold is intended to be used in a broad range of surgical procedures to reinforce soft tissue where weakness exists, and can be used with ...
By Biorez Inc.
-
CoNextions Inc. Announces First Patient Treated with Coronet Soft Tissue Fixation System, a Revolutionary Tenodesis Product
CoNextions Inc. (www.conextionsmed.com), an innovator in tendon repair, announced today the first patient has been treated with the Coronet Soft Tissue Fixation System in a Kidner procedure. The Kidner procedure is the most common surgical treatment for a painful accessory navicular bone that causes foot/tendon pain. The Coronet Soft Tissue Fixation Systems is a tenodesis device intended for the ...
-
CoNextions Inc. Announces FDA 510(k) Clearance of Coronet System, a Revolutionary Tenodesis Product
CoNextions Inc. (www.conextionsmed.com) announced today that it received a 510(k) clearance (K200028) from the U.S. Food and Drug Administration (FDA) for CoronetTM System, a tenodesis product intended for the fixation of tissue to bone and tissue to tissue. The Coronet’s novel design improves the soft tissue fixation strength of these repairs compared to conventional suture repairs. A ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you